Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Feasibility in Elderly mCRPC (GERICO10)
NCT01254513Phase 2Completed
- Sponsor
- Unicancer
- Start
- Dec 2010
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Unicancer. Started Dec 2010; status: completed.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01254513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254513.